Experimental mitochondrial vaccine takes on advanced cancers
NCT ID NCT06927297
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an engineered mitochondrial vaccine in 12 people with advanced solid tumors who cannot have standard treatments. The vaccine is given as a series of shots to see if it is safe and can help control the cancer. The study focuses on safety first, with early signs of effectiveness also being measured.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- engineered mitochondrial vaccine
- What this could lead to
- If it works, this could point toward a new way to treat advanced solid tumors by training the immune system to attack cancer cells.
- What could go wrong
- This is a very early, small Phase 1 trial with only 12 participants, so it is mainly checking safety. The vaccine may not shrink tumors or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?